US equities
|
NVDA
$135.12
▼-7.44%
ANT
$84.88
▼-12.65%
MU
$600.71
▼-13.00%
AMD
$434.20
▼-11.24%
AAPL
$345.60
▼-1.03%
SPCX
$129.33
▼-6.57%
MSFT
$488.05
▼-2.06%
AMZN
$249.41
▼-3.09%
NVDA
$135.12
▼-7.44%
ANT
$84.88
▼-12.65%
MU
$600.71
▼-13.00%
AMD
$434.20
▼-11.24%
AAPL
$345.60
▼-1.03%
SPCX
$129.33
▼-6.57%
MSFT
$488.05
▼-2.06%
AMZN
$249.41
▼-3.09%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Cornerstone Pharmaceuticals
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
September 28, 2022
From
Cornerstone Pharmaceuticals
Via
GlobeNewswire
Tickers
RFL